Status:
RECRUITING
Safety Follow-up Study of Participants Dosed With INV-347 in Study INV-CL-108
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Obesity
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The study looks at the safety and blood levels of the study drug INV-347 in participants who were previously dosed with INV-347 in study INV-CL-108. Participants will not get any study drug in this st...
Eligibility Criteria
Inclusion
- Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
- Male or female (sex at birth).
- Age 18 years or above at the time of signing the informed consent.
- Previously dosed with INV-347 in study INV-CL-108 and with measurable INV-347 concentration in plasma at enrolment \[above lower limit of qualification (LLOQ) of 0.5 nanogram per milliliter (ng/mL)\].
Exclusion
- The study has no exclusion criteria.
Key Trial Info
Start Date :
August 6 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 15 2027
Estimated Enrollment :
91 Patients enrolled
Trial Details
Trial ID
NCT07153172
Start Date
August 6 2025
End Date
September 15 2027
Last Update
September 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Syneos Health
Québec, Canada, G1P 0A2